IDH2 and central nervous system cancer: The underrepresentation of IDH-mutant astrocytomas (only 8 of 34 patients, including three with WHO CNS grade 2, two with grade 3, and three with grade 4) limits the generalizability of our findings, particularly to lower-grade glioma populations where seizure incidence is higher.